Impact of the adjuvant management and risk factors on survival in FIGO stage 3 endometrial cancer patients
Authors:
Open Access
- 6 April 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13
Abstract
Objective: Patients with FIGO stage III endometrial cancer routinely receive adjuvant therapy. The purpose of this study was to evaluate overall survival (OS) and disease-free survival (DFS) in patients with stage IIIA to IIIC2 patients by treatment modality received and risk factors.Materials/methods: Patients with stage III endometrial cancer treated from 2000-2010 were identified in the provincial cancer registry. Clinicopathologic characteristics, adjuvant treatments and outcomes were compared using descriptive and multivariable analyses.Results: 261 patients had stage 3 endometrial cancer, 132 with stage IIIA, 9 with IIIB, 85 with IIIC1 and 35 with IIIC2. 39 had FIGO grade 1 disease; 73, grade 2; 147, grade 3. 160 had endometrioid and 35 had serous carcinoma. 161 patients received sequential adjuvant chemotherapy (CT) and radiotherapy (RT); 33 received RT only; 32 received CT only; 35 received neither. 5-year (5Y) DFS and OS were similar among stage IIIA (DFS 46.7%, OS 58.5%), IIIB (DFS 50.8%, OS 58.5%), IIIC1 (DFS 44%, OS 49.9%) and IIIC2 (DFS 42%, OS 41.6%). Use of adjuvant RT was associated with improved median DFS (53.7 vs 14.7m, p<0.00001) and OS (61.9 vs 25.7m, p<0.00001) compared to no RT. Likewise, use of adjuvant CT was also associated with improved DFS (54.8 vs 16.5m, p<0.00001) and OS (62.9 vs 26.5m, p50%, and no adjuvant RT or CT were identified as adversely impacting DFS and OS.Conclusion: In stage III endometrial cancer patients, use of both chemotherapy and radiation therapy was associated with improved DFS and OS and therefore should be recommended in all eligible patients after resection.Keywords
This publication has 12 references indexed in Scilit:
- Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based studyEuropean Journal of Cancer, 2020
- Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trialThe Lancet Oncology, 2019
- Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial CancerNew England Journal of Medicine, 2019
- Adjuvant therapy in stage III endometrial cancer confined to the pelvisGynecologic Oncology, 2019
- Benefit of combination chemotherapy and radiation stratified by grade of stage IIIC endometrial cancerGynecologic Oncology, 2017
- Chemoradiation versus chemotherapy or radiation alone in stage III endometrial cancer: Patterns of care and impact on overall survivalGynecologic Oncology, 2016
- Endometrial cancerThe Lancet, 2016
- Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancerJournal of Gynecologic Oncology, 2015
- Adjuvant chemotherapy for advanced endometrial cancerCochrane Database of Systematic Reviews, 2014
- Revised FIGO staging for carcinoma of the vulva, cervix, and endometriumInternational Journal of Gynecology & Obstetrics, 2009